Recombinant paraoxonase 1 protects against sarin and soman toxicity following microinstillation inhalation exposure in guinea pigs

Toxicology Letters

Volumn 202, Issue 3, 2011, Pages 203-208

  Valiyaveettil, Manojkumar ^a   Alamneh, Yonas ^a   Rezk, Peter ^b   Perkins, Michael W ^b   Sciuto, Alfred M ^b   Doctor, Bhupendra P ^a   Nambiar, Madhusoodana P ^a,c  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

^c Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

Catalytic bioscavenger; Chemical warfare nerve agents; Paraoxonase 1; Recombinant protein; Trichoplusia ni larvae

Indexed keywords

ACETYLCHOLINESTERASE; ARYLDIALKYLPHOSPHATASE 1; CHOLINESTERASE; RECOMBINANT ENZYME; SARIN; SOMAN;

ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CONTROLLED STUDY; ENZYME ACTIVITY; GUINEA PIG; MALE; NONHUMAN; OXYGEN SATURATION; PRIORITY JOURNAL; PULSE RATE; SURVIVAL RATE;

ACUTE LUNG INJURY; ANIMALS; ARYLDIALKYLPHOSPHATASE; BRAIN; CHEMICAL WARFARE AGENTS; CHOLINESTERASES; GUINEA PIGS; HUMANS; INHALATION EXPOSURE; INJECTIONS, INTRAVENOUS; INSTILLATION, DRUG; KAPLAN-MEIER ESTIMATE; LONGEVITY; MALE; NEUROPROTECTIVE AGENTS; OXYGEN; RABBITS; RECOMBINANT PROTEINS; SARIN; SOMAN;

ANIMALIA; CAVIA; TRICHOPLUSIA NI;

EID: 79954619209     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2011.02.007     Document Type: Article

References (39)

1. Aldridge W.N., Davison A.N. The mechanism of inhibition of cholinesterases by organophosphorus compounds. Biochem. J. 1953, 55:763-766.
2. Bajgar J. Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv. Clin. Chem. 2004, 38:151-216.
3. Boado R.J., Hui E.K., Lu J.Z., Pardridge W.M. CHO cell expression, long-term stability, and primate pharmacokinetics and brain uptake of an IgG-paroxonase-1 fusion protein. Biotechnol. Bioeng. 2011, 108:186-196.
4. Boesch-Saadatmandi C., Egert S., Schrader C., Coumol X., Barouki R., Muller M.J., Wolffram S., Rimbach G. Effect of quercetin on paraoxonase 1 activity - studies in cultured cells, mice and humans. J. Physiol. Pharmacol. 2010, 61:99-105.
5. Che M.M., Conti M., Boylan M., Sciuto A.M., Gordon R.K., Nambiar M.P. Blood and bronchoalveolar lavage fluid acetylcholinesterase levels following microinstillation inhalation exposure to sarin in Guinea pigs. Inhal. Toxicol. 2008, 20:821-828.
6. Costa L.G., Cole T.B., Furlong C.E. Polymorphisms of paraoxonase (PON1) and their significance in clinical toxicology of organophosphates. J. Toxicol. Clin. Toxicol. 2003, 41:37-45.
7. Costa L.G., Cole T.B., Furlong C.E. Paraoxonase (PON1): from toxicology to cardiovascular medicine. Acta Biomed. 2005, 76(2 Suppl.):50-57.
8. Costa L.G., Cole T.B., Vitalone A., Furlong C.E. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin. Chim. Acta 2005, 352:37-47.
9. Costa L.G., Giordano G., Furlong C.E. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem. Pharmacol. 2011, 81:337-344.
10. Costa L.G., Vitalone A., Cole T.B., Furlong C.E. Modulation of paraoxonase (PON1) activity. Biochem. Pharmacol. 2005, 69:541-550.
11. Doctor B.P., Raveh L., Wolfe A.D., Maxwell D.M., Ashani Y. Enzymes as pretreatment drugs for organophosphate toxicity. Neurosci. Biobehav. Rev. 1991, 15:123-128.
12. Doctor B.P., Saxena A. Bioscavengers for the protection of humans against organophosphate toxicity. Chem. Biol. Interact. 2005, 157-158:167-171.
13. Duysen E.G., Parikh K., Aleti V., Manne V., Lockridge O., Chilukuri N. Adenovirus-mediated human paraoxonase1 gene transfer to provide protection against the toxicity of the organophosphorus pesticide toxicant diazoxon. Gene Ther. 2010, 136. 10.1038/gt.2010.136.
14. Ellman G.L., Courtney K.D., Andres V., Feather-Stone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7:88-95.
15. Flynn C.J., Wecker L. Elevated choline levels in brain. A non-cholinergic component of organophosphate toxicity. Biochem. Pharmacol. 1986, 35:3115-3121.
16. Fu A.L., Wang Y.X., Sun M.J. Naked DNA prevents soman intoxication. Biochem. Biophys. Res. Commun. 2005, 328:901-905.
17. Furlong C.E., Cole T.B., Walter B.J., Shih D.M., Tward A., Lusis A.J., Timchalk C., Richter R.J., Costa L.G. Paraoxonase 1 (PON1) status and risk of insecticide exposure. J. Biochem. Mol. Toxicol. 2005, 19:182-183.
18. Gaidukov L., Bar D., Yacobson S., Naftali E., Kaufman O., Tabakman R., Tawfik D.S., Levy-Nissenbaum E. In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes. BMC. Clin. Pharmacol. 2009, 9:18.
19. Gouedard C., Barouki R., Morel Y. Induction of the paraoxonase-1 gene expression by resveratrol. Arterioscler. Thromb. Vasc. Biol. 2004, 24:2378-2383.
20. Grillberger L., Kreil T.R., Nasr S., Reiter M. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol. J. 2009, 4:186-201.
21. Harel M., Aharoni A., Gaidukov L., Brumshtein B., Khersonsky O., Meged R., Dvir H., Ravelli R.B., McCarthy A., Toker L., Silman I., Sussman J.L., Tawfik D.S. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol. 2004, 11:412-419.
22. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 1993, 3:73-76.
23. Josse D., Masson P. Human plasma paraoxonase (HuPON1): an anti-atherogenic enzyme with organophosphate hydrolase activity. Ann. Pharm. Fr. 2001, 59:108-118.
24. Lenz D.E., Maxwell D.M., Koplovitz I., Clark C.R., Capacio B.R., Cerasoli D.M., Federko J.M., Luo C., Saxena A., Doctor B.P., Olson C. Protection against soman or VX poisoning by human butyrylcholinesterase in guinea pigs and cynomolgus monkeys. Chem. Biol. Interact. 2005, 157-158:205-210.
25. Lenz D.E., Yeung D., Smith J.R., Sweeney R.E., Lumley L.A., Cerasoli D.M. Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: a mini review. Toxicology 2007, 233:31-39.
26. Li W.F., Furlong C.E., Costa L.G. Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol. Lett. 1995, 76:219-226.
27. Mackness B., Durrington P.N., Mackness M.I. The paraoxonase gene family and coronary heart disease. Curr. Opin. Lipidol. 2002, 13:357-362.
28. Nambiar M.P., Gordon R.K., Moran T.S., Richards S.M., Sciuto A.M. A simple method for accurate endotracheal placement of an intubation tube in Guinea pigs to assess lung injury following chemical exposure. Toxicol. Mech. Methods 2007, 17:385-392.
29. Nambiar M.P., Wright B.S., Rezk P.E., Smith K.B., Gordon R.K., Moran T.S., Richards S.M., Sciuto A.M. Development of a microinstillation model of inhalation exposure to assess lung injury following exposure to toxic chemicals and nerve agents in Guinea pigs. Toxicol. Mech. Methods 2006, 16:295-306.
30. Otto T.C., Harsch C.K., Yeung D.T., Magliery T.J., Cerasoli D.M., Lenz D.E. Dramatic differences in organophosphorus hydrolase activity between human and chimeric recombinant mammalian paraoxonase-1 enzymes. Biochemistry 2009, 48:10416-10422.
31. Otto T.C., Kasten S.A., Kovaleva E., Liu Z., Buchman G., Tolosa M., Davis D., Smith J.R., Balcerzak R., Lenz D.E., Cerasoli D.M. Purification and characterization of functional human paraoxonase-1 expressed in Trichoplusia ni larvae. Chem. Biol. Interact. 2010, 187:388-392.
32. Perkins M.W., Pierre Z., Rezk P., Sabnekar P., Kabra K., Chanda S., Oguntayo S., Sciuto A.M., Doctor B.P., Nambiar M.P. Acute respiratory toxicity following inhalation exposure to soman in guinea pigs. Toxicol. Appl. Pharmacol. 2010, 245:171-178.
33. Primo-Parmo S.L., Sorenson R.C., Teiber J., La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996, 33:498-507.
34. Rochu D., Chabriere E., Masson P. Human paraoxonase: a promising approach for pre-treatment and therapy of organophosphorus poisoning. Toxicology 2007, 233:47-59.
35. Sorenson R.C., Bisgaier C.L., Aviram M., Hsu C., Billecke S., La Du B.N. Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler. Thromb. Vasc. Biol. 1999, 19:2214-2225.
36. Stevens R.C., Suzuki S.M., Cole T.B., Park S.S., Richter R.J., Furlong C.E. Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:12780-12784.
37. Valiyaveettil M., Alamneh Y., Biggemann L., Soojhawon I., Doctor B.P., Nambiar M.P. Efficient hydrolysis of the chemical warfare nerve agent tabun by recombinant and purified human and rabbit serum paraoxonase 1. Biochem. Biophys. Res. Commun. 2010, 403:97-102.
38. Valiyaveettil M., Alamneh Y., Rezk P., Biggemann L., Perkins M., Sciuto A.M., Doctor B.P., Nambiar M.P. Protective efficacy of catalytic bioscavenger; paraoxonase 1 against sarin and soman exposure in guinea pigs. Biochem. Pharmacol. 2011, 81:800-809.
39. Wang N.N., Dai H., Yuan L., Han Z.K., Sun J., Zhang Z., Zhao M. Study of paraoxonase-1 function on tissue damage of dichlorvos. Toxicol. Lett. 2010, 196:125-132.